Ribavirin
Ribavirin is a guanine derivative approved for treating Human
coronavirus (HCV) and respiratory syncytial virus (RSV), evaluated in
patients with SARS and MERS, but it has side effects, such as anaemia
might prove severe at high doses [12] and whether it could offer
sufficient potency against 2019-nCoV is uncertain [15]. Ribavirin,
in high concentrations such as (Half- Effective Concentration (EC50) =
109.50 μM, Half- Concentration (CC50) > 400 μM, Selectivity
Index (SI) > 3.65) was needed to minimize viral infection
[10] and, according to preliminary results, may prove to be
resistance to COVID-19.